Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor
Xin Li, … , Finn Cilius Nielsen, Claus Storgaard Sørensen
Xin Li, … , Finn Cilius Nielsen, Claus Storgaard Sørensen
Published April 22, 2025
Citation Information: JCI Insight. 2025;10(11):e186747. https://doi.org/10.1172/jci.insight.186747.
View: Text | PDF
Research Article Cell biology Clinical Research Genetics

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor

  • Text
  • PDF
Abstract

Mutations in genome maintenance factors drive sporadic and hereditary breast cancers. Here, we searched for potential drivers based on germline DNA analysis from a cohort consisting of patients with early-onset breast cancer negative for BRCA1/BRCA2 mutations. This revealed candidate genes that subsequently were subjected to RNA interference–based (RNAi-based) phenotype screens to reveal genome integrity effects. We identified several genes with functional roles in genome maintenance, including Glucose-6-Phosphatase Catalytic Subunit 3 (G6PC3), SMC4, and CCDC108. Notably, G6PC3-deficient cells exhibited increased levels of γH2AX and micronuclei formation, along with defects in homologous recombination (HR) repair. Consistent with these observations, G6PC3 was required for the efficient recruitment of BRCA1 to sites of DNA double-strand breaks (DSBs). RNA-Seq analysis revealed that G6PC3 promotes the expression of multiple homologous recombination repair genes, including BRCA1. Through CRISPR-Select functional-genetic phenotype analysis of G6PC3 germline mutations, we identified 2 germline G6PC3 variants displaying partial loss of function. Furthermore, our study demonstrated that G6pc3 deficiency accelerates mammary tumor formation induced by Trp53 loss in mice. In conclusion, our cohort-based functional analysis has unveiled genome maintenance factors and identified G6PC3 as a potential candidate tumor suppressor in breast cancer.

Authors

Xin Li, Maria Rossing, Ana Moisés da Silva, Muthiah Bose, Thorkell Gudjónsson, Jan Benada, Jayashree Thatte, Jens Vilstrup Johansen, Judit Börcsök, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Asma Tajik, Lucía Sena, Zoltan Szallasi, Morten Frödin, Jos Jonkers, Finn Cilius Nielsen, Claus Storgaard Sørensen

×

Figure 3

G6PC3 promotes homologous recombination.

Options: View larger image (or click on image) Download as PowerPoint
G6PC3 promotes homologous recombination.
(A) Schematic illustration of t...
(A) Schematic illustration of the DR-GFP assay to measure homologous recombination efficiency. (B and C) Flow cytometry–based quantification of HR efficiency in U2OS cells after siRNA (B) or CRISPR gRNAs treatment (C). Ratios were normalized to the values obtained with control siRNA (siUNC) or nontreated cells (NTC). (D) Representative confocal images of RPA in U2OS cells. Scale bar: 5 μm. Cells were treated with indicated siRNA (30 nM) for 48 hours. DNA DSBs were induced using 5 Gy IR, and cells were fixed and imaged after 6 hours. (E) Bar plot indicate RPA foci levels (per cell) in S/G2 phase. (F) Representative image of cell cycle estimation by QIBC for RPA foci analysis. (G) Representative confocal images of BRCA1 in U2OS cells. Experiments were performed as in D, except DNA DSBs were induced using 2 Gy IR and cells were fixed and imaged after 1 hour. (H) Bar plot indicate BRCA1 foci levels (per cell) in S/G2 phase. (I) Representative image of cell cycle estimation by QIBC for BRCA1 foci analysis. (J and K) Dose response matrix for cell viability 5-day treatment after IR (J) or Talazoparib (K) in combination with G6PC3 siRNA in U2OS cells; data represent mean from triplicate. (L) qPCR was used to determine G6PC3 expression. U2OS cells were transfected with different concentration of siRNA for 48 hours. Data are shown as mean ± SD from 3 biological replicates; statistical significance of differences was evaluated using 1-way ANOVA followed by Dunnett’s test. *P < 0.05, **P < 0.01, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts